Vitrification has detrimental effects on maturation, viability, and subcellular quality of oocytes post IVM in cancerous women: An experimental study

Abstract

Background: In vitro maturation (IVM) of immature oocytes retrieved from ovarian tissue has been considered as a valuable approach for fertility preservation in cancerous patients.
Objective: To evaluate the efficacy of vitrification on oocyte maturation, survival rates, as well as the subcellular oocyte quality post IVM.
Materials and Methods: The ovarian cortexes from 19 women with cervix and uterine malignancy aged 21–39 yr were collected. Cumulus-oocyte complexes were aspirated from all visible antral follicles. 102 immature oocytes were collected, and 43 oocytes were detected appropriately for IVM (control group). Also, 59 immature oocytes were vitrified, then matured in vitro (IVM) in two groups: with Growth/differentiation factor
9 (GDF9) (group 1) and without GDF9 (group 2) supplementation. Rates of oocytes viability, maturation, and survival along with meiotic spindle visualization and zona pellucida birefringence were assessed with Polyscope.
Results: The rate of maturation was significantly higher in controls (55.8%) compared to the other groups. Maturation rate was 23.3% in oocytes cultured in IVM medium enriched with GDF9, and 27.6% in those cultured in IVM medium lacking GDF9 (p= 0.86). Also, the meiotic spindle was present in 74.4% of control oocytes which
was significantly higher than the other groups. The proportion of high zona pellucida birefringence was higher in the controls when compared with group 1 (51.2% vs. 23.3%, respectively, p = 0.04).
Conclusion: Vitrification had a detrimental effect on oocyte maturation, viability as well as the subcellular quality of the oocytes after IVM in cancerous women.

References
[1] Demeestere I, Basso O, Moffa F, Peccatori F, Poirot C, Shalom-Paz E. Fertility preservation in female cancer
patients. Obstet Gynecol Int 2012; 2012: 695041.

[2] Gonzalez C, Boada M, Devesa M, Veiga A. Concise review: fertility preservation: an update. Stem Cells Transl Med 2012; 1: 668–672.
[3] Wunder D, Perey L, Reseau Romand Cancer et F, Achtari C, Ambrosetti A, Bellavia M, et al. Fertility preservation in cancer patients. Review of the French speaking part of Switzerland and recommendations for different situations. Swiss Med Wkly 2012; 142: w13645.

[4] Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31: 2500–2510.

[5] Wilken-Jensen HN, Kristensen SG, Jeppesen JV, Yding Andersen C. Developmental competence of oocytes isolated from surplus medulla tissue in connection with cryopreservation of ovarian tissue for fertility preservation. Acta Obstet Gynecol Scand 2014; 93: 32–37.

[6] Nazari S, Khalili MA, Esmaielzadeh F, Mohsenzadeh M. Maturation capacity, morphology and morphometric
assessment of human immature oocytes after vitrification and in-vitro maturation. Iran J Reprod Med 2011; 9: 209–216.

[7] Creux H, Monnier P, Son WY, Tulandi T, Buckett W. Immature oocyte retrieval and in vitro oocyte maturation
at different phases of the menstrual cycle in women with cancer who require urgent gonadotoxic treatment. Fertil Steril 2017; 107: 198–204.

[8] Prasath EB, Chan ML, Wong WH, Lim CJ, Tharmalingam MD, Hendricks M, et al. First pregnancy and live birth
resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian
cancer patient. Hum Reprod 2014; 29: 276–278.

[9] Ashourzadeh S, Khalili MA, Omidi M, Mahani SN, Kalantar SM, Aflatoonian A, et al. Noninvasive assays of in vitro matured human oocytes showed insignificant correlation with fertilization and embryo development. Arch Gynecol Obstet 2015; 292: 459–463.

[10] Omidi M, Khalili MA, Ashourzadeh S, Rahimipour M. Zona pellucida birefringence and meiotic spindle visualization of human oocytes are not influenced by IVM technology. Reprod Fertil Dev 2014; 26: 407–413.

[11] Safian F, Khalili MA, Ashourzadeh S, Omidi M. Analysis of meiotic spindle and zona pellucida birefringence of IVM oocytes in PCOS patients. Turk J Med Sci 2017; 47: 368–373.

[12] Gode F, Gulekli B, Dogan E, Korhan P, Dogan S, Bige O, et al. Influence of follicular fluid GDF9 and BMP15 on embryo quality. Fertil Steril 2011; 95: 2274–2278.

[13] Yeo CX, Gilchrist RB, Thompson JG, Lane M. Exogenous growth differentiation factor 9 in oocyte maturation media enhances subsequent embryo development and fetal viability in mice. Hum Reprod 2008; 23: 67–73.

[14] Safian F, Khalili MA, Karimi-Zarchi M, Mohsenzadeh M, Ashourzadeh S, Omidi M. Developmental competence of immature oocytes aspirated from antral follicles in patients with gynecological diseases. Iran J Reprod Med 2015; 13: 507–512.

[15] Swiatecka J, Bielawski T, Anchim T, Lesniewska M, Milewski R, Wolczynski S. Oocyte zona pellucida and
meiotic spindle birefringence as a biomarker of pregnancy rate outcome in IVF-ICSI treatment. Ginekol Pol 2014; 85: 264–271.

[16] Yazdanpanah F, Khalili MA, Eftekhar M, Karimi H. The effect of vitrification on maturation and viability capacities of immature human oocytes. Arch Gynecol Obstet 2013; 288: 439–444.

[17] Yin H, Jiang H, Kristensen SG, Andersen CY. Vitrification of in vitro matured oocytes collected from surplus ovarian medulla tissue resulting from fertility preservation of ovarian cortex tissue. J Assist Reprod Genet 2016; 33: 741–746.

[18] Fasano G, Dechene J, Antonacci R, Biramane J, Vannin AS, Van Langendonckt A, et al. Outcomes of immature oocytes collected from ovarian tissue for cryopreservation in adult and prepubertal patients. Reprod Biomed Online 2017; 34: 575–582.

[19] Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod 2011; 26: 1768–1774.

[20] Ji J, Liu Y, Tong XH, Luo L, Ma J, Chen Z. The optimum number of oocytes in IVF treatment: an analysis of 2455
cycles in China. Hum Reprod 2013; 28: 2728–2734.

[21] Mohsenzadeh M, Salehi-Abargouei A, Tabibnejad N, Karimi-Zarchi M, Khalili MA. Impact of vitrification on
human oocytes before and after in vitro maturation: A systematic review and meta-analysis. Eur J Obstet Gynecol
Reprod Biol 2018; 227: 19–26.

[22] Mohsenzadeh M, Khalili MA, Nazari S, Jahromi VH, Agharahimi A, Halvaei I. Effect of vitrification on morphology and in-vitro maturation outcome of human immature oocytes. Ital J Anat Embryol 2012; 117: 190–198.

[23] Wininger JD, Kort HI. Cryopreservation of immature and mature human oocytes. Semin Reprod Med 2002; 20: 45–49.

[24] Cao YX, Chian RC. Fertility preservation with immature and in vitro matured oocytes. Semin Reprod Med 2009; 27:456–464.

[25] Coticchio G, Bonu MA, Borini A, Flamigni C. Oocyte cryopreservation: a biological perspective. Eur J Obstet
Gynecol Reprod Biol 2004; 115 (Suppl.): S2–S7

[26] Fasano G, Demeestere I, Englert Y. In-vitro maturation of human oocytes: before or after vitrification? J Assist Reprod Genet 2012; 29: 507–512.

[27] Mohsenzadeh M, Khalili MA, Tabibnejad N, Yari N, AghaRahimi A, Karimi-Zarchi M. Embryo cryopreservation following in-vitro maturation for fertility preservation in a woman with mullerian adenosarcoma: A case report. J
Hum Reprod Sci 2017; 10: 138–141.

[28] Peng J, Li Q, Wigglesworth K, Rangarajan A, Kattamuri C, Peterson RT, et al. Growth differentiation factor 9:
bone morphogenetic protein 15 heterodimers are potent regulators of ovarian functions. Proc Nati Acad Sci USA
2013; 110: E776–E785.

[29] Hayashi M, McGee EA, Min G, Klein C, Rose UM, van Duin M, et al. Recombinant growth differentiation factor-9 (GDF9) enhances growth and differentiation of cultured early ovarian follicles. Endocrinology 1999; 140: 1236–1244.

[30] Hreinsson JG, Scott JE, Rasmussen C, Swahn ML, Hsueh AJ, Hovatta O. Growth differentiation factor-9 promotes the growth, development, and survival of human ovarian follicles in organ culture. J Clin Endocrinol Metab 2002;87: 316–321.

[31] Imesch P, Scheiner D, Xie M, Fink D, Macas E, Dubey R, et al. Developmental potential of human oocytes matured in vitro followed by vitrification and activation. J Ovarian Res 2013; 6: 30.
[32] Anzai M, Nishiwaki M, Yanagi M, Nakashima T, Kaneko T, Taguchi Y, et al. Application of laser-assisted zona drilling to in vitro fertilization of cryopreserved mouse oocytes with spermatozoa from a subfertile transgenic mouse. J Reprod Dev 2006; 52: 601–606.

[33] Ding DC, Chu TY, Chang YH. Achieving oocyte survival and stable spindles after vitrification using closed pulled straws regardless of zona status. Tzu Chi Medical Journal 2012; 24: 186–190.

[34] Cobo A, Diaz C. Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2011; 96: 277–285.

[35] Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril 2006; 86: 70–80.

[36] Coticchio G, Bromfield JJ, Sciajno R, Gambardella A, Scaravelli G, Borini A, et al. Vitrification may increase the
rate of chromosome misalignment in the metaphase II spindle of human mature oocytes. Reprod Biomed Online
2009; 19 (Suppl.): 29–34.

[37] Lierman S, Tilleman K, Braeckmans K, Peynshaert K, Weyers S, T’Sjoen G, et al. Fertility preservation for trans
men: frozen-thawed in vitro matured oocytes collected at the time of ovarian tissue processing exhibit normal
meiotic spindles. J Assist Reprod Genet 2017; 34: 1449–1456.

[38] de Almeida Ferreira Braga DP, de Cassia Savio Figueira R, Queiroz P, Madaschi C, Iaconelli AJr, Borges EJr. Zona pellucida birefringence in in vivo and in vitro matured oocytes. Fertil Steril 2010; 94: 2050–2053.

[39] Petersen CG, Vagnini LD, Mauri AL, Massaro FC, Silva LF, Cavagna M, et al. Evaluation of zona pellucida birefringence intensity during in vitro maturation of oocytes from stimulated cycles. Reprod Biol Endocrinol 2011; 9: 53.